{
    "organizations": [],
    "uuid": "cbcbab5eb48523d4766e6233e62bfafd5fd15f31",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-karyopharm-announces-positive-top/brief-karyopharm-announces-positive-top-line-data-from-phase-2b-storm-study-evaluating-selinexor-in-patients-with-penta-refractory-multiple-myeloma-idUSFWN1S71C4",
    "ord_in_thread": 0,
    "title": "BRIEF-Karyopharm Announces Positive Top-Line Data From Phase 2b STORM Study Evaluating Selinexor In Patients With Penta-Refractory Multiple Myeloma",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "April 30 (Reuters) - Karyopharm Therapeutics Inc:\n* KARYOPHARM ANNOUNCES POSITIVE TOP-LINE DATA FROM PHASE 2B STORM STUDY EVALUATING SELINEXOR IN PATIENTS WITH PENTA-REFRACTORY MULTIPLE MYELOMA\n* KARYOPHARM THERAPEUTICS INC - SELINEXOR CONTINUES TO DEMONSTRATE A PREDICTABLE AND MANAGEABLE TOLERABILITY PROFILE\n* KARYOPHARM THERAPEUTICS INC - COMPANY PLANS TO SUBMIT A NEW DRUG APPLICATION TO FDA IN SECOND HALF OF 2018\n* KARYOPHARM THERAPEUTICS INC - REGARDING STORM STUDYâ€™S PRIMARY OBJECTIVE, ORAL SELINEXOR ACHIEVED A 25.4% OVERALL RESPONSE RATE\n* KARYOPHARM THERAPEUTICS INC - PLANS TO SUBMIT A MARKETING AUTHORIZATION APPLICATION TO EUROPEAN MEDICINES AGENCY IN EARLY 2019\n* KARYOPHARM THERAPEUTICS INC - EXPECTING TO COMPLETE ENROLLMENT IN BOSTON STUDY BY END OF 2018, WITH TOP-LINE DATA ANTICIPATED IN 2019 Source text for Eikon: Further company coverage:\n ",
    "published": "2018-05-01T04:30:00.000+03:00",
    "crawled": "2018-05-01T19:54:15.018+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "april",
        "reuters",
        "karyopharm",
        "therapeutic",
        "inc",
        "karyopharm",
        "announces",
        "positive",
        "data",
        "phase",
        "2b",
        "storm",
        "study",
        "evaluating",
        "selinexor",
        "patient",
        "multiple",
        "myeloma",
        "karyopharm",
        "therapeutic",
        "inc",
        "selinexor",
        "continues",
        "demonstrate",
        "predictable",
        "manageable",
        "tolerability",
        "profile",
        "karyopharm",
        "therapeutic",
        "inc",
        "company",
        "plan",
        "submit",
        "new",
        "drug",
        "application",
        "fda",
        "second",
        "half",
        "karyopharm",
        "therapeutic",
        "inc",
        "regarding",
        "storm",
        "study",
        "primary",
        "objective",
        "oral",
        "selinexor",
        "achieved",
        "overall",
        "response",
        "rate",
        "karyopharm",
        "therapeutic",
        "inc",
        "plan",
        "submit",
        "marketing",
        "authorization",
        "application",
        "european",
        "medicine",
        "agency",
        "early",
        "karyopharm",
        "therapeutic",
        "inc",
        "expecting",
        "complete",
        "enrollment",
        "boston",
        "study",
        "end",
        "data",
        "anticipated",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}